Beyond Biologics: Evaluating Efficacy of Dexamethsone
Cyclophosphamide Pulse Therapy and Conventional Corticosteroid
Therapy in Pemphigus Vulgaris in Resource Limited Settings

doi:10.61705/jdcr.19.2.2026.28.38

Contents

Abstract
Keywords

Download PDF pdf

Download XML

345 Views

363 Downloads

Share this article

Research Article | Volume 19 Issue 2 (Apr-Jun, 2026) | Pages 28 - 38

Beyond Biologics: Evaluating Efficacy of Dexamethsone Cyclophosphamide Pulse Therapy and Conventional Corticosteroid Therapy in Pemphigus Vulgaris in Resource Limited Settings

Pratibha Sharma

Gopal Kashyap

Damini Shaktawat

Archana Paliwal

Mohammed Shoaib

⁴

Assistant professor, Department of Dermatology, Mahatma Gandhi Medical College & Hospital, Jaipur (Rajasthan)

Associate professor, Department of Microbiology, Mahatma Gandhi Medical College & Hospital, Jaipur (Rajasthan)

Professor Department of Community Medicine, Mahatma Gandhi Medical College & Hospital, Jaipur (Rajasthan)

⁴

Assistant Professor, Dept. of Pharmacology, Sudha Medical College & Hospital, Kota (Rajasthan)

Under a Creative Commons license

Open Access

DOI : 10.61705/jdcr.19.2.2026.28.38

Received

March 26, 2026

Revised

April 4, 2026

Accepted

April 4, 2026

Published

April 10, 2026

Abstract

Pemphigus vulgaris is a chronic autoimmune blistering disorder of skin and mucosal surfaces. Treatment consists mainly of corticosteroids given either in moderate to high oral doses or in the form of intravenous pulse therapy along with adjuvant immunosuppressant. Recently rituximab, an anti CD20 monoclonal antibody, has been approved as first line treatment. With recent advancements and targeted molecular therapies,treatment of pemphigus has been revolutionized. But looking at their high cost, pulse therapy with fewer side effects and with high and rapid remission rates, remains a treatment option in pemphigus in resource limited settings..

Keywords

Pemphigus

Dexamethasone Cyclophosphamide Pulse therapy (DCP)

Conventional Corticosteroid regime (CCR)

Rituximab

PDAI (Pemphigus Disease Area Index)

DLQI (Dermatology Life Quality Index).

Recommended Articles

Research Article

A Rare Case of Morphine-Induced Bullous Sweet Syndrome

Nicholas Chin, BS ,

...

Ann Lin, DO

Published: 20/08/2026

Download Read Article

Research Article

Chronic Spontaneous Urticaria with Coexisting Cholinergic Urticaria and Monoclonal Gammopathy: A Diagnostic Challenge in the Differential Diagnosis of Schnitzler Syndrome – A Case Report

Łukasz Moos ,

...

Zenon Brzoza

Published: 20/08/2026